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See related research by Khaleel et al., http://breast-cancer-research.com/content/16/6/486We read with interest the article by Khaleel and col-
leagues reporting a new prognostic signature in hor-
mone receptor (HR)-positive breast cancer based on
mRNA expression of target genes of the E2F4 transcrip-
tion factor [1]. The clinical relevance comes from its
independent prognostic value and its biological signifi-
cance (mainly regulation of cell cycle and proliferation,
reflecting high E2F4 activity). When compared with
patients with low score for the signature (low risk),
patients with high score (high risk) showed shorter
relapse-free survival, making them candidates for adju-
vant chemotherapy. Whereas adjuvant chemotherapy is
recommended for most human epidermal growth fac-
tor receptor 2 (HER2)-positive or triple-negative tu-
mors, indications are more challenging for HR+/HER2−
tumors, which are candidates for either adjuvant hor-
mone therapy alone or both hormone therapy and
chemotherapy.
We wondered whether high-risk HR+/HER2− tumors
were more chemosensitive than low-risk HR+/HER2−
tumors. We gathered gene expression data for 1,247
breast cancers treated with neoadjuvant anthracycline-
based chemotherapy and with available pathological re-
sponse (Additional file 1), pathological complete response
(pCR) being defined as no residual invasive cancer in the
breast and axillary lymph nodes. All cases were assigned a
relapse risk according to the metagene based on average* Correspondence: bertuccif@ipc.unicancer.fr
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dataset. We analyzed the predictive value of the E2F4
metagene for the pathological response to chemotherapy
in the 582 HR+/HER2− tumors (12% pCR rate). High-risk
tumors were associated (Additional file 2) with ductal type,
grade 3, and higher pCR rate, which was 17% versus 8% in
the low-risk tumors (P <0.001). As expected, grade 3 was
also associated with higher pCR rate (Table 1). In multi-
variate analysis, the E2F4 metagene remained predictive
for pCR (P = 0.027), whereas grade did not. Interestingly,
mRNA expression of E2F4 itself did not predict for the re-
sponse to chemotherapy, demonstrating the interest of the
metagene as a better indicator of E2F4 function than E2F4
expression level alone.
HR+/HER2− tumors with an E2F4 high-risk signature
were more sensitive to anthracycline-based chemother-
apy than low-risk tumors, as already reported with other
prognostic signatures [2,3] – including in the adjuvant
setting [4,5], where high-risk tumors showed greater
benefit from chemotherapy than low-risk tumors. The
next step will be to test, retrospectively in randomized
prospective trials of adjuvant chemotherapy, the hypoth-
esis that the difference in relapse between patients
treated with chemotherapy and untreated patients is lar-
ger in the high-risk group than in the low-risk group.
Interest in the E2F4 signature is probably higher than
expected.l. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Univariate and multivariate analyses for pathological complete response
Univariate analysis Multivariate analysis
n Odds ratio (95% CI) P value n Odds ratio (95% CI) P value
Age, >50 years versus ≤50 years 582 0.79 (0.51 to 1.21) 0.37
Histological type
ILC versus IDC 240 2.60 (0.71 to 8.12) 0.19
Other versus IDC 1.09 (0.49 to 2.26) 0.85
Clinical tumor size, cT2 to cT4 versus cT1 580 0.88 (0.44 to 2.01) 0.79
Clinical axillary lymph node status, cN1 to cN3 versus cN0 571 1.37 (0.86 to 2.23) 0.27
Grade
2 versus 1 529 1.32 (0.43 to 5.98) 0.72 529 1.22 (0.40 to 5.52) 0.80
3 versus 1 5.56 (1.93 to 24.4) 2.09E-02 4.37 (1.48 to 19.4) 0.05
E2F4 metagene-based classification, high risk versus low risk 582 2.40 (1.57 to 3.72) 7.98E-04 529 1.86 (1.14 to 3.08) 4.02E-02
CI, confidence interval; IDC, invasive ductal cancer; ILC, invasive lobular cancer. Bold data indicate significance.
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Additional file 1: Table S1. Presenting a description of the eight public
breast cancer datasets.
Additional file 2: Table S2. Presenting the E2F4 metagene-based
classification and clinicopathological correlations.
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